CARLO GAMBACORTI PASSERINI

Has grant

Full Professor of Hematology

University of Milano-Bicocca

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Carlo Gambacorti Passerini is a Full Professor of Hematology at Università degli Studi di Milano-Bicocca, Italy. His research focuses on chronic myeloid leukemia, treatment strategies involving tyrosine kinase inhibitors, and the management of hematological malignancies. Recent publications include studies on the efficacy of pirtobrutinib, the impact of age on treatment tolerability, and advancements in molecular genetics related to leukemia.

Recent Grants

Grant: Close

"MOLECULAR PATHOGENESIS OF ATYPICAL CHRONIC MYELOID LEUKEMIA - (acml) and of blast crisis (bc) PROGRESSION IN CML - ID 14249

Open Date: 2014-01-01

Close Date: 2016-12-01

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (7)

Elisabetta Abruzzese

UNIVERSITY TOR VERGATA

ITALY

View details

Roberto Chiarle

University of Turin

ITALY

View details

Luca Mologni

University of Milano-Bicocca

ITALY

View details

Tim Brümmendorf

Head

University Hospital RWTH Aachen

GERMANY

View details

Laura Antolini

Associate Professor

University of Milano-Bicocca

ITALY

View details

Rocco Piazza

University of Milano-Bicocca

ITALY

View details

Valentin Garcia

Profesor Asociado

Universidad de Alcalá

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

CARLO GAMBACORTI PASSERINI

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study – SIMPLICITY

Reconstructing CML guidelines for first line treatment from two different points of view

Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib

Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial

Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1

Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia

Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia

Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies

Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction

Collaborators (7)

Elisabetta Abruzzese

Roberto Chiarle

Luca Mologni

Tim Brümmendorf

Laura Antolini

Rocco Piazza

Valentin Garcia

Make your next move.